The increasing use of moderate (< 35 fractions) and extreme (< 5 fractions) hypofractionated radiation therapy in prostate cancer is yielding favorable results, both in terms of maintained biochemical response and toxicity.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Several hypofractionation (HF) schemes for the treatment of prostate cancer are available, although there is considerable variability in the techniques used to manage intra-/interfraction motion and deliver radiation doses. We performed a review of the published studies on HF regimens as a topic of interest for the Stereotactic Ablative Radiotherapy working group, which is part of the Italian Association of Medical Physics. Aspects of organ motion management (imaging for contouring, target volume definition, and rectum/bladder preparation) and treatment delivery (prostate localization, image guided radiation therapy strategy and frequency) were evaluated and categorized to assess outcome relative to disease control and toxicity. Despite the heterogeneity of the data, some interesting trends that emerged from the review might be useful in identifying an optimum HF strategy.
Clemente S, Nigro R, Oliviero C, Marchioni C, Esposito M, Giglioli FR, Mancosu P, Marino C, Russo S, Stasi M, Strigari L, Veronese I, Landoni V. Are you the author?
Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata Rionero in Vulture, Potenza, Italy; Azienda Sanitaria Locale Rieti, Roma, Italy; Azienda Sanitaria, Firenze, Italy; Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy; Humanitas Clinical and Research Hospital, Rozzano, Milano, Italy; Humanitas Centro Catanese di Oncologia, Catania, Italy; Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Italy; Istituto Nazionale Tumori Regina Elena, Roma, Italy; Universita' degli Studi di Milano, Milano, Italy.
Reference: Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):182-195.